Novo Nordisk A/S
Should You Buy Eli Lilly Stock Before April 10?
A catalyst for stock performance may be just ahead.
Source: Motley Fool Mar 22, 2026
Hims & Hers (HIMS) Tumbles 8.86% on Market Bloodbath, Profit-Taking
Hims & Hers Health Inc. (NYSE:HIMS) is one of the 10 Stock Market Casualties You Can’t Ignore Today. Hims & Hers fell by 8.86 percent on Friday to close at $22.02 apiece, as investors unloaded positions amid a combination of market pessimism and profit-taking, having soared by as much as 88 percent already this month.
Source: Insider Monkey Mar 21, 2026
Beijing courts Eli Lilly as weight-loss drug race drives $3bn China commitment
Investing.com -- Eli Lilly and Company (NYSE:LLY) is deepening its footprint in the world’s second-largest economy, with Chinese Commerce Minister Wang Wentao expressing hope that the pharmaceutical giant will "deepen its commitment" and pursue more aggressive growth targets.
Source: Investing.com Mar 21, 2026
Does Hims & Hers (HIMS) Novo Nordisk Deal Quietly Redraw Its Risk Reward Profile?
Earlier in March 2026, Novo Nordisk agreed to resume selling its weight-loss drugs through the Hims & Hers Health platform, ending a public legal conflict over copycat medications and restoring a commercial relationship in one of healthcare’s most competitive categories. Days later, Hims & Hers appointed veteran communicator Kathryn Beiser as Chief Communications Officer, underscoring the company’s focus on strengthening its brand and explaining its broader telehealth ambitions to...
Source: Simply Wall St. Mar 21, 2026
Why The Hims & Hers Health (HIMS) Story Is Resetting After Novo Deal And New Guidance
The modeled fair value for Hims & Hers Health has been revised from about US$44.36 to around US$23.69, a reset of roughly 47% in the price target framework. This shift aligns with Street commentary that balances enthusiasm around the renewed Novo Nordisk GLP-1 agreement with concerns related to recent results, 2026 guidance, legal and regulatory risk, and execution on new offerings. As you read on, you will see how these factors shape the evolving analyst narrative and what to watch...
Source: Simply Wall St. Mar 20, 2026
Novo Nordisk Stock Decline: Challenges and Valuation in 2026
An analysis of Novo Nordisk's sustained stock price decline, driven by weak results and guidance, strategic moves to counter challenges, and the potential investment opportunity presented by its current low valuation.
Source: IndexBox Mar 20, 2026
- Insulin (bulk)
- Medical syringes (with or without needles)
- Disposable syringes
- Blood testing instruments
- Blood glucose meters
- Bioreactor for culture of micro-organisms
- Plastic packaging containers
- Human growth hormone
- Synthetic organic coloring matter
- Vitamins and derivatives
- Lactose for pharmaceutical use
- Pharmaceutical grade water
- Vaccine for human medicine
- Industrial centrifuges
- Active pharmaceutical ingredients (apis)
- Plastic bottles for pharmaceuticals
- Reagents for blood tests
- Diagnostic kits
- Pharmaceutical glass tubes
- Lab freezers
- Corticosteroid drugs
- Proteins for therapeutic use
- Pain relief drugs
- Anesthetic products
- Single-use bioreactor bags
- Alcoholic solutions for disinfection
- Bio-based cleaning agents
- Pharmaceutical manufacturing equipment
- Chromatography columns
- Hormone replacement therapy drugs
- Prefilled syringes
- Disposable insulin pen
- Blood glucose monitor
- Diabetes test strips
- Liraglutide
- Anti-obesity preparation
- Estrogen replacement therapy
- Oral diabetes medications
- Antidiabetic combination medications
- Thrombolytic agents
- Blood thinners
- Capacity building medications
- Growth hormone-releasing hormone
- Insulin glargine
- Insulin aspart
- Insulin degludec
- Rapid-acting insulin
- Long-acting insulin
- Hemostasis management device
- Diabetes test lancet
- Insulin pumps
- Novopen injector
- Reusable insulin pen
- Human growth hormone (somatropin)
- Intranasal somatropin
- Blood clotting factors
- Protein-based pharmaceuticals
- Biopharmaceuticals
- Diabetes management software
- Surgical and medical instruments
IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.
All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.